Argenx stock gains as Q2 2026 growth and AI drug-discovery deal support momentum

Argenx stock is trading near a new 52-week high after the immunology specialist’s strong Q2 2026 numbers and fresh partnerships kept investor interest high. According to a recent performance overview dated September 2, 2026, Argenx SE (ISIN NL0010832176) shares on NASDAQ closed at 1,028.51 USD, with intraday trading reaching 1,069.00 USD and marking a new one-year high in the current reporting cycle.

Q2 2026 figures underpin the rally

For the current reporting year, the numbers behind the Argenx story are central to the stock’s momentum. A healthcare-focused analysis on Yahoo Finance highlighted that Argenx delivered 18 consecutive quarters of revenue growth, with sales rising 60% year over year in Q2 2026 and 17% sequentially versus Q1 2026, underscoring an acceleration in the top line during the latest quarter.The same Yahoo Finance overview noted that Argenx reported earnings of 472 million USD in Q2 2026, nearly doubling profit compared with the prior-year quarter, which points to significant operating leverage as the company scales its immunology portfolio.

For investors, the combination of 60% revenue growth and a near 100% earnings increase versus Q2 2025 positions Q2 2026 as a pivotal quarter in the current cycle. The analysis also emphasized that operating margins expanded alongside the top-line growth in Q2 2026, signaling that Argenx is not only growing rapidly but also improving profitability as its key therapies gain traction.The detailed Q2 2026 discussion frames these figures as a core reason why the stock’s valuation remains supported at elevated levels.

Stock near its 52-week high on NASDAQ and in Brussels

The strong fundamental backdrop is reflected in the latest market data. A MarketBeat alert dated September 2, 2026 described how Argenx shares on NASDAQ hit a new 52-week high, with intraday trading reaching 1,069.00 USD and the last trade reported at 1,057.92 USD compared with a prior close of 1,028.51 USD, confirming that the price move pushed the stock into new territory within its one-year range.The MarketBeat price alert framed the high as a fresh one-year peak and noted that analyst sentiment remains constructive.

On the European side, Argenx’s listing on Euronext Brussels provides an additional price reference that is relevant for DACH-region investors who follow the BEL 20 index. According to a recent quote overview on Yahoo Finance for the ARGX.BR ticker, Argenx shares in Brussels closed at 897.60 EUR on September 2, 2026, up 2.09% on the day, with the stock positioned near the upper part of its local trading range.This same overview contrasts Argenx’s performance with the BEL 20 index, highlighting that the stock has outperformed the broader Belgian benchmark over the past year.

AI-driven preclinical partnership adds strategic depth

Beyond the headline figures, Argenx is also advancing its early-stage pipeline through technology partnerships. On September 2, 2026, BenchSci announced a two-year enterprise agreement with Argenx aimed at accelerating AI-driven preclinical drug discovery, signaling that Argenx is investing in data-rich approaches to find and validate new immunology targets.The BenchSci press release describes the agreement as a two-year enterprise collaboration designed to apply AI to preclinical data, streamlining how Argenx identifies promising candidates for further development.

From an investor’s perspective, the AI partnership complements the company’s robust commercial growth by aiming to improve productivity in the earlier stages of the R&D funnel. While the agreement itself does not carry immediate revenue figures, it supports the medium-term thesis that Argenx can sustain its 18-quarter revenue growth streak by sharpening the selection of future clinical assets. Combined with the Q2 2026 numbers, this technology-driven initiative underscores that the company is working on both near-term profitability and long-term innovation capacity.

Vyvgart as a key commercial pillar

Argenx’s current revenue trajectory is closely linked to its lead therapy Vyvgart, an Fc receptor antagonist used in autoimmune diseases such as generalized myasthenia gravis. Revenue growth of 60% year over year in Q2 2026 indicates that uptake of Vyvgart and its formulations remains strong, especially as the drug expands into additional indications and geographies. The 17% sequential increase versus Q1 2026 suggests that demand is not only stable but accelerating quarter over quarter, which typically reflects both new patient starts and continued therapy adherence in chronic indications.

For retail investors analyzing Argenx stock, Vyvgart’s performance matters because it is the core driver of the company’s current earnings profile. With Q2 2026 earnings reaching 472 million USD, nearly double the profit in Q2 2025, the product is now contributing enough scale to push operating margins higher as fixed costs are spread over a growing revenue base. In this context, regulatory and market developments around Vyvgart will likely remain central to the Argenx story in the coming quarters, even as AI-based discovery work and partnerships broaden the pipeline beyond existing indications.

Stock price context and investor takeaway

As of the most recent completed trading day on September 2, 2026, Argenx stock closed at 1,028.51 USD on NASDAQ according to a detailed quote snapshot, with intraday trading having reached 1,069.00 USD that same day, a level identified as a new one-year high in the MarketBeat alert. The closing price therefore stands below the intraday peak but still in the upper part of the quoted 52-week range, which underlines that the market is willing to value Argenx near cycle highs following the strong Q2 2026 report and ongoing partnerships.A corporate news summary of these developments reiterates that the stock’s recent high is anchored in the underlying fundamental momentum.

For investors considering Argenx stock in the broader healthcare context, the current situation combines several elements: a clear acceleration in revenue and earnings in Q2 2026, expanded operating margins, a stock price that has moved to a new 52-week high on NASDAQ, and a two-year AI-driven discovery agreement that aims to sustain pipeline productivity. Together, these data points suggest that Argenx has entered a phase in which execution on both commercial and R&D fronts will be closely watched by the market, with the latest quarterly figures setting a high bar for subsequent results.